ASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and...

Related Keywords

Zhejiang ,China ,Hong Kong ,United States ,Hangzhou ,Suzhou ,Jiangsu ,Chicago ,Illinois ,Guangzhou ,Guangdong ,Jilin ,Rockville ,Melbourne ,Victoria ,Australia ,Chinese ,American ,Yuxiang Ma ,Haibo Qiu ,Masa Lasica ,Prnewswire Ascentage Pharma ,Huafeng Wang ,Ascentage Pharma ,Yifan Zhai ,Md Anderson Cancer Center ,American Society Of Clinical Oncology ,Sun Yat Sen University Cancer Center ,Zhejiang University School Of Medicine ,Major National ,Dana Farber Cancer Institute ,China National Medical Products Administration ,National Reimbursement Drug List ,Astrazeneca ,Clinical Oncology ,Annual Meeting ,Oral Reports ,Chief Medical Officer ,Central Time ,Hematologic Malignancies ,Myelodysplastic Syndromes ,First Affiliated Hospital ,Zhejiang University School ,Chronic Lymphocytic ,Developmental Therapeutics ,Molecularly Targeted Agents ,Main Board ,Stock Exchange ,Hong Kong Limited ,Major National Rd Projects ,Major New Drug Projects ,New Drug Incubator ,Innovative Drug Programs ,Major Project ,Priority Review Designations ,Breakthrough Therapy Designations ,Drug Evaluation ,Reimbursement Drug List ,Orphan Drug Designation ,Fast Track Designation ,Orphan Designation ,Cancer Center ,Mayo Clinic ,